Cautionary optimism: caffeine and Parkinson's disease risk.
Most Parkinson's disease (PD) patients present without known family history and without a diagnosed prodromal phase, underscoring the difficulty of employing primary (neuroprevention) and secondary (neuroprotection) preventions. In cases of monogenic forms, however, potential gene-carrying family members of a proband could engage in neuroprevention, such as exercise or diet modifications, to attenuate the risk of, or delay, disease development. However, a historical lack of recognized disease-modifying interventions has limited clinicians' ability to recommend reliable preventive measures in caring for at-risk populations. We briefly analyze the first retrospective study to examine caffeine consumption and PD risk in a LRRK2 R1628P cohort.
Department of Neurology, James J and Joan A. Gardner Center for Parkinson's disease and Movement Disorders, University of Cincinnati, Cincinnati, OH USA.
Leonard L
LL
Sokol
Harvard Medical School, Boston, MA USA.
Michael J
MJ
Young
Department of Neurology, James J and Joan A. Gardner Center for Parkinson's disease and Movement Disorders, University of Cincinnati, Cincinnati, OH USA.
Alberto J
AJ
Espay
Department of Neurology, L7-305 Montreal General Hospital, 1650 Cedar Avenue, Montreal, QC H3G1A4 Canada.
Ronald B
RB
Postuma
Caffeine; LRRK2; Parkinson’s disease; Risk factors